120 related articles for article (PubMed ID: 11751012)
21. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
22. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
23. Ehrlich tumor inhibition using doxorubicin containing liposomes.
Elbialy NS; Mady MM
Saudi Pharm J; 2015 Apr; 23(2):182-7. PubMed ID: 25972739
[TBL] [Abstract][Full Text] [Related]
24. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
26. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes.
Han HD; Lee A; Song CK; Hwang T; Seong H; Lee CO; Shin BC
Int J Pharm; 2006 Apr; 313(1-2):181-8. PubMed ID: 16540270
[TBL] [Abstract][Full Text] [Related]
27. [Characterization and cytotoxicity of mixed PEG-DSG modified liposomes].
Sadzuka Y; Tsuruda T; Sonobe T
Yakugaku Zasshi; 2005 Jan; 125(1):149-57. PubMed ID: 15635286
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
[TBL] [Abstract][Full Text] [Related]
29. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
30. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
31. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38.
Mayhew EG; Goldrosen MH; Vaage J; Rustum YM
J Natl Cancer Inst; 1987 Apr; 78(4):707-13. PubMed ID: 3470546
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
33. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
34. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy.
Ning S; Macleod K; Abra RM; Huang AH; Hahn GM
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):827-34. PubMed ID: 8040030
[TBL] [Abstract][Full Text] [Related]
35. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
36. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
37. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice.
Emanuel N; Kedar E; Bolotin EM; Smorodinsky NI; Barenholz Y
Pharm Res; 1996 Jun; 13(6):861-8. PubMed ID: 8792423
[TBL] [Abstract][Full Text] [Related]
38. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
39. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
Xu DH; Gao JQ; Liang WQ
Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
[TBL] [Abstract][Full Text] [Related]
40. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
